A Study on PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.